<!DOCTYPE html>
<html lang="tr">
<head>
<link rel="icon" type="image/png" sizes="32x32" href="/favicon.png"><link rel="icon" type="image/png" sizes="16x16" href="/favicon-16.png">
<script src="/scripts/https-redirect.js"></script>
<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-QBM7E0EHFP"></script>
<script>
 window.dataLayer = window.dataLayer || [];
 function gtag(){dataLayer.push(arguments);}
 gtag('js', new Date());
 gtag('config', 'G-QBM7E0EHFP');
</script>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>GLP-1 Ä°laÃ§larÄ± BÄ±rakÄ±ldÄ±ÄŸÄ±nda Ne Oluyor? | UzunYaÅŸa</title>
    <meta property="og:image" content="https://uzunyasa.com/images/og-default.png">
 <meta name="description" content="Ozempic, Wegovy veya Mounjaro'yu bÄ±rakmayÄ± dÃ¼ÅŸÃ¼nÃ¼yor musunuz? Klinik Ã§alÄ±ÅŸma verileri, kilo geri alÄ±m oranlarÄ± ve sÃ¼rdÃ¼rÃ¼lebilir stratejiler.">
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&family=Playfair+Display:wght@500;600&display=swap" rel="stylesheet">
 <link rel="stylesheet" href="../../styles/main.css">
 <link rel="stylesheet" href="../../styles/animations.css">
 <style>
 article { max-width: 800px; margin: 0 auto; padding: 7rem 2rem 4rem; }
 .post-meta-top { display: flex; gap: 1rem; flex-wrap: wrap; margin-bottom: 1.5rem; }
 .post-category { display: inline-block; background: #8b5cf6; color: white; padding: 0.4rem 1rem; border-radius: 20px; font-size: 0.8rem; font-weight: 600; }
 .reading-time { color: var(--text-gray); font-size: 0.9rem; }
 h1 { font-family: 'Playfair Display', serif; font-size: 2.4rem; font-weight: 600; line-height: 1.2; margin-bottom: 1rem; }
 .subtitle { font-size: 1.15rem; color: var(--text-gray); margin-bottom: 2rem; }
 .featured-image { width: 100%; height: 300px; background: linear-gradient(135deg, rgba(139,92,246,0.7), rgba(124,58,237,0.7)), url("https://images.unsplash.com/photo-1576091160550-2173dba999ef?w=800&q=80") center/cover; border-radius: 16px; margin-bottom: 2rem; display: flex; align-items: center; justify-content: center; }
 .featured-image span { font-size: 4rem; }
 .content p { margin-bottom: 1.5rem; font-size: 1.05rem; }
 .content h2 { font-size: 1.5rem; font-weight: 700; margin: 2.5rem 0 1rem; color: var(--primary); padding-top: 1rem; border-top: 1px solid #e5e7eb; }
 .content h3 { font-size: 1.2rem; font-weight: 600; margin: 1.5rem 0 0.75rem; }
 .content ul, .content ol { margin: 1.5rem 0; padding-left: 1.5rem; }
 .content li { margin-bottom: 0.5rem; }
 .warning-box { background: #fef2f2; border-left: 4px solid #ef4444; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
 .info-box { background: #eff6ff; border-left: 4px solid #3b82f6; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
 .success-box { background: #f0fdf4; border-left: 4px solid #10b981; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1.5rem 0; }
 .stat-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(140px, 1fr)); gap: 1rem; margin: 2rem 0; }
 .stat-card { background: white; border: 1px solid #e5e7eb; border-radius: 12px; padding: 1.25rem; text-align: center; }
 .stat-card .number { font-size: 1.75rem; font-weight: 800; color: #ef4444; }
 .stat-card .label { font-size: 0.8rem; color: var(--text-gray); }
 table { width: 100%; border-collapse: collapse; margin: 1.5rem 0; font-size: 0.9rem; }
 th, td { padding: 0.75rem; text-align: left; border-bottom: 1px solid #e5e7eb; }
 th { background: #f8fafc; font-weight: 600; }
 .cta-box { background: linear-gradient(135deg, var(--primary), #2a7d83); color: white; padding: 2rem; border-radius: 16px; text-align: center; margin: 3rem 0; }
 .cta-btn { display: inline-block; background: white; color: var(--primary); padding: 0.75rem 1.5rem; border-radius: 8px; text-decoration: none; font-weight: 600; }
 
 @media (max-width: 640px) { h1 { font-size: 1.8rem; } article { padding: 6rem 1rem 3rem; } }
 </style>

    <meta property="og:title" content="GLP-1 Ä°laÃ§larÄ± BÄ±rakÄ±ldÄ±ÄŸÄ±nda Ne Oluyor?">
    <meta property="og:description" content="Ozempic, Wegovy veya Mounjaro'yu bÄ±rakmayÄ± dÃ¼ÅŸÃ¼nÃ¼yor musunuz? Klinik Ã§alÄ±ÅŸma verileri, kilo geri alÄ±m oranlarÄ± ve sÃ¼rdÃ¼rÃ¼lebilir stratejiler.">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://uzunyasa.com/pages/blog/glp1-birakinca-ne-olur.html">
    <meta property="og:image" content="https://uzunyasa.com/images/og-default.png">
    <meta property="og:site_name" content="UzunYaÅŸa">
    <meta property="og:locale" content="tr_TR">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="GLP-1 Ä°laÃ§larÄ± BÄ±rakÄ±ldÄ±ÄŸÄ±nda Ne Oluyor?">
    <meta name="twitter:description" content="Ozempic, Wegovy veya Mounjaro'yu bÄ±rakmayÄ± dÃ¼ÅŸÃ¼nÃ¼yor musunuz? Klinik Ã§alÄ±ÅŸma verileri, kilo geri alÄ±m oranlarÄ± ve sÃ¼rdÃ¼rÃ¼lebilir stratejiler.">
    <link rel="canonical" href="https://uzunyasa.com/pages/blog/glp1-birakinca-ne-olur.html">
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": "GLP-1 Ä°laÃ§larÄ± BÄ±rakÄ±ldÄ±ÄŸÄ±nda Ne Oluyor? | UzunYaÅŸa",
  "description": "Ozempic, Wegovy veya Mounjaro",
  "author": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "url": "https://uzunyasa.com"
  },
  "publisher": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "logo": {
      "@type": "ImageObject",
      "url": "https://uzunyasa.com/images/logo-icon-new.png"
    }
  },
  "datePublished": "2026-02-01",
  "dateModified": "2026-02-24",
  "mainEntityOfPage": "https://uzunyasa.com/pages/blog/glp1-birakinca-ne-olur.html",
  "image": "https://uzunyasa.com/images/og-default.png"
}
</script>
</head>
<body>
 <header class="header">
 <div class="header-inner">
 <a href="../../index.html"><img src="../../images/logo.svg" alt="UzunYaÅŸa" class="logo-img"></a>
 <a href="../blog.html" class="back-link">â† Blog</a>
 </div>
 </header>

 <article>
 <div class="post-meta-top">
 <span class="post-category"> Ã–nemli Bilgi</span>
 <span class="reading-time">â± 12 dk okuma â€¢ Åubat 2026</span>
 </div>
 
 <h1>GLP-1 Ä°laÃ§larÄ± BÄ±rakÄ±ldÄ±ÄŸÄ±nda Ne Oluyor?</h1>
 <p class="subtitle">Ozempic, Wegovy veya Mounjaro'yu bÄ±rakmayÄ± dÃ¼ÅŸÃ¼nÃ¼yor musunuz? Klinik Ã§alÄ±ÅŸma verileri, kilo geri alÄ±m oranlarÄ± ve sÃ¼rdÃ¼rÃ¼lebilir stratejiler.</p>

 <div class="featured-image"></div>

 <div class="stat-grid">
 <div class="stat-card"><div class="number">%67</div><div class="label">Kaybedilen kilonun geri alÄ±mÄ±</div></div>
 <div class="stat-card"><div class="number">1 yÄ±l</div><div class="label">Geri alÄ±m sÃ¼resi</div></div>
 <div class="stat-card"><div class="number">%82.5</div><div class="label">Ã–nemli geri alÄ±m yaÅŸayan</div></div>
 </div>

 <div class="content">
 <div class="warning-box">
 <strong> Kritik UyarÄ±:</strong> Bu yazÄ±, GLP-1 ilaÃ§larÄ±nÄ±n bÄ±rakÄ±lmasÄ±nÄ±n sonuÃ§larÄ±nÄ± bilimsel verilerle anlatmaktadÄ±r. Ä°laÃ§ bÄ±rakma kararÄ±nÄ± mutlaka doktorunuzla birlikte verin.
 </div>

 <h2>Neden Bu Kadar Ã–nemli?</h2>
 <p>GLP-1 ilaÃ§larÄ± hakkÄ±nda konuÅŸulurken genellikle kilo kaybÄ± rakamlarÄ± Ã¶ne Ã§Ä±kar. Ancak Ã§oÄŸu hasta iÃ§in asÄ±l soru ÅŸu: "Bu ilacÄ± Ã¶mÃ¼r boyu kullanmak zorunda mÄ±yÄ±m?" Cevap, ne yazÄ±k ki, Ã§oÄŸu hasta iÃ§in "evet" yÃ¶nÃ¼nde.</p>

 <h2>Klinik Ã‡alÄ±ÅŸma Verileri</h2>

 <h3>STEP 1 UzantÄ±sÄ± (Semaglutid)</h3>
 <p>327 katÄ±lÄ±mcÄ±, 68 hafta tedavi sonrasÄ± ilaÃ§ kesildi ğŸŸ¢ (STEP-1 uzantÄ±sÄ±, RKÃ‡, n=1.961; Wilding ve ark., 2022):</p>
 <ul>
 <li>Tedavi dÃ¶neminde (uzantÄ± alt grubu): <strong>%17.3</strong> kilo kaybÄ±</li>
 <li>BÄ±rakÄ±ldÄ±ktan 1 yÄ±l sonra: <strong>%5.6</strong> kilo kaybÄ± kaldÄ±</li>
 <li>Geri alÄ±nan: <strong>~11.7 puan</strong> (kaybÄ±n ~%67'si)</li>
 </ul>

 <h3>SURMOUNT-4 (Tirzepatid)</h3>
 <p>36 haftalÄ±k aÃ§Ä±k etiketli tirzepatid tedavisi sonrasÄ± ilaÃ§ kesilen grup ğŸŸ¢ (SURMOUNT-4, RKÃ‡, n=783; Aronne ve ark., 2024):</p>
 <ul>
 <li>BÄ±rakÄ±ldÄ±ktan 52 haftada: <strong>14.0 puan</strong> geri alÄ±ndÄ±</li>
 <li><strong>%82.5</strong> hasta, kaybÄ±n â‰¥%25'ini geri aldÄ±</li>
 <li>Sadece <strong>%17.5</strong> minimal geri alÄ±m gÃ¶sterdi</li>
 </ul>

 <h3>Kardiyometabolik Parametreler</h3>
 <p>Sadece kilo deÄŸil, saÄŸlÄ±k gÃ¶stergeleri de geri dÃ¶nÃ¼yor ğŸŸ¢ (STEP-1 uzantÄ±sÄ±; Wilding ve ark., 2022):</p>
 <table>
 <tr><th>Parametre</th><th>Tedavi Sonunda</th><th>BÄ±rakÄ±ldÄ±ktan 1 YÄ±l Sonra</th></tr>
 <tr><td>Bel Ã§evresi</td><td>-13.5 cm</td><td>-5.0 cm</td></tr>
 <tr><td>Sistolik KB</td><td>-6.2 mmHg</td><td>-0.5 mmHg</td></tr>
 <tr><td>HbA1c</td><td>-0.5%</td><td>-0.1%</td></tr>
 <tr><td>CRP</td><td>-55%</td><td>-17%</td></tr>
 </table>

 <h2>Neden Kilo Geri Geliyor?</h2>
 <div class="info-box">
 <strong>Biyolojik GerÃ§eklik:</strong>
 <ul>
 <li>GLP-1 ilaÃ§larÄ±, vÃ¼cudun doÄŸal aÃ§lÄ±k-tokluk sistemini etkiler</li>
 <li>Ä°laÃ§ bÄ±rakÄ±ldÄ±ÄŸÄ±nda bu etki ortadan kalkar</li>
 <li>VÃ¼cut, "set point" teorisine gÃ¶re eski kilosuna dÃ¶nmeye Ã§alÄ±ÅŸÄ±r ğŸŸ¡ (teorik model; klinik gÃ¶zlemlerle desteklenir)</li>
 <li>AÃ§lÄ±k hormonlarÄ± (ghrelin) yeniden yÃ¼kselir</li>
 </ul>
 </div>

 <p><strong>Ã–nemli:</strong> Bu, sizin iradenizin zayÄ±flÄ±ÄŸÄ± deÄŸil â€” biyolojik bir gerÃ§ekliktir. Hipertansiyon ilacÄ±nÄ± bÄ±raktÄ±ÄŸÄ±nÄ±zda tansiyon nasÄ±l yÃ¼kselirse, GLP-1'i bÄ±raktÄ±ÄŸÄ±nÄ±zda kilo da Ã¶yle geri gelir.</p>

 <h2>Kilo Geri AlÄ±mÄ±nÄ± Azaltma Stratejileri</h2>

 <h3>1. YapÄ±landÄ±rÄ±lmÄ±ÅŸ Egzersiz</h3>
 <div class="success-box">
 <strong>Egzersiz ve Kilo Koruma:</strong> Klinik Ã§alÄ±ÅŸmalar, dÃ¼zenli egzersizin GLP-1 tedavisi sonrasÄ± kilo koruma olasÄ±lÄ±ÄŸÄ±nÄ± anlamlÄ± Ã¶lÃ§Ã¼de artÄ±rdÄ±ÄŸÄ±nÄ± gÃ¶stermektedir ğŸŸ¡ (gÃ¶zlemsel veriler; kesin oran Ã§alÄ±ÅŸmaya gÃ¶re deÄŸiÅŸir).
 </div>
 <ul>
 <li>Haftada 150+ dakika orta yoÄŸunluklu kardio</li>
 <li>Haftada 2-3 gÃ¼n direnÃ§ antrenmanÄ±</li>
 <li>GÃ¼nlÃ¼k 7.000-10.000 adÄ±m</li>
 </ul>

 <h3>2. YÃ¼ksek Protein Diyeti</h3>
 <ul>
 <li>GÃ¼nde 1.2-1.6 g/kg protein ğŸŸ¢ (ESPEN, 2021); aktif direnÃ§ antrenmanÄ± yapanlarda 1.6-2.2 g/kg hedeflenebilir</li>
 <li>Her Ã¶ÄŸÃ¼nde protein Ã¶ncelikli</li>
 <li>Kas kÃ¼tlesini korumaya yardÄ±mcÄ±</li>
 </ul>

 <h3>3. Kademeli Doz Azaltma</h3>
 <p>Ani bÄ±rakma yerine yavaÅŸ yavaÅŸ azaltma:</p>
 <ul>
 <li>Doktorunuzla planlÄ± azaltma programÄ±</li>
 <li>Her 4-6 haftada bir kademe dÃ¼ÅŸÃ¼rme</li>
 <li>VÃ¼cuda adaptasyon sÃ¼resi tanÄ±ma</li>
 </ul>

 <h3>4. Alternatif Tedavilere GeÃ§iÅŸ</h3>
 <ul>
 <li><strong>Oral GLP-1:</strong> Orforglipron gibi yeni oral seÃ§enekler</li>
 <li><strong>DÃ¼ÅŸÃ¼k doz sÃ¼rdÃ¼rme:</strong> Tam doz yerine dÃ¼ÅŸÃ¼k dozda devam</li>
 <li><strong>ESG:</strong> Endoskopik prosedÃ¼r ile kalÄ±cÄ± Ã§Ã¶zÃ¼m</li>
 </ul>

 <h2>Ne Zaman BÄ±rakÄ±labilir?</h2>
 <p>BazÄ± durumlar bÄ±rakmayÄ± gerektirebilir:</p>
 <ul>
 <li>Hamilelik planÄ± (en az 2 ay Ã¶nce bÄ±rakÄ±lmalÄ±)</li>
 <li>Ciddi yan etkiler (Ã§Ã¶zÃ¼lemeyen GI sorunlarÄ±)</li>
 <li>Maliyet/eriÅŸim sorunlarÄ±</li>
 <li>Medikal kontraendikasyon geliÅŸmesi</li>
 </ul>

 <h2>SonuÃ§</h2>
 <p>GLP-1 ilaÃ§larÄ±, obezite tedavisinde etkili araÃ§lardÄ±r â€” ancak "kÃ¼r" deÄŸildir. BÄ±rakÄ±ldÄ±ÄŸÄ±nda kilo geri gelir ğŸŸ¢ (STEP-1 uzantÄ±sÄ± ve SURMOUNT-4 verileri). Bu, ilacÄ±n baÅŸarÄ±sÄ±zlÄ±ÄŸÄ± deÄŸil, kronik bir hastalÄ±ÄŸÄ±n (obezite) doÄŸasÄ±dÄ±r.</p>

 <p><strong>SeÃ§enekleriniz:</strong></p>
 <ol>
 <li>Uzun vadeli/Ã¶mÃ¼r boyu GLP-1 kullanÄ±mÄ±</li>
 <li>DÃ¼ÅŸÃ¼k dozda sÃ¼rdÃ¼rme tedavisi</li>
 <li>Alternatif tedavilere geÃ§iÅŸ (ESG, cerrahi)</li>
 <li>YaÅŸam tarzÄ± deÄŸiÅŸiklikleriyle desteklenen kademeli bÄ±rakma</li>
 </ol>

 <section class="references">
 <h2>Kaynaklar</h2>
 <ol>
 <li>Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." <em>Diabetes Obes Metab</em>, 2022;24(8):1553-1564. DOI: 10.1111/dom.14725. PMID: 35441470.</li>
 <li>Aronne LJ, et al. "Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4)." <em>JAMA</em>, 2024;331(1):38-48. DOI: 10.1001/jama.2023.24945. PMID: 38078870.</li>
 <li>Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity (STEP 1)." <em>N Engl J Med</em>, 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183. PMID: 33567185.</li>
 <li>Rubino D, et al. "Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial." <em>JAMA</em>, 2021;325(14):1414-1425. DOI: 10.1001/jama.2021.3224. PMID: 33755728.</li>
 <li>Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)." <em>N Engl J Med</em>, 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038. PMID: 35658024.</li>
 <li>Lincoff AM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)." <em>N Engl J Med</em>, 2023;389(24):2221-2232. DOI: 10.1056/NEJMoa2307563. PMID: 37952131.</li>
 <li>Sumithran P, et al. "Long-term persistence of hormonal adaptations to weight loss." <em>N Engl J Med</em>, 2011;365(17):1597-1604. DOI: 10.1056/NEJMoa1105816. PMID: 22029981.</li>
 <li>Garvey WT, et al. "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial." <em>Nat Med</em>, 2022;28(10):2083-2091. DOI: 10.1038/s41591-022-02026-4. PMID: 36216945.</li>
 </ol>
 </section>

 <!-- BLOG SUMMARY - Auto-generated -->
 <div class="blog-summary" style="margin-top: 4rem; padding-top: 2rem; border-top: 2px solid #e5e7eb;">
 <div style="display: flex; align-items: center; gap: 12px; margin-bottom: 1.5rem;">
 <div style="width: 4px; height: 32px; background: linear-gradient(to bottom, #195157, #2a7d83); border-radius: 2px;"></div>
 <h2 style="margin: 0; font-family: 'Playfair Display', serif; font-size: 1.75rem; color: #195157;">Ã–zet</h2>
 </div>
 
 <blockquote style="margin: 0 0 1.5rem 0; padding: 1.5rem 2rem; background: linear-gradient(135deg, #f0fdf4 0%, #ecfeff 100%); border-left: 4px solid #195157; border-radius: 0 12px 12px 0; font-size: 1.1rem; line-height: 1.8; color: #374151; font-style: italic;">
 Ozempic, Wegovy veya Mounjaro'yu bÄ±rakmayÄ± dÃ¼ÅŸÃ¼nÃ¼yor musunuz? Klinik Ã§alÄ±ÅŸma verileri, kilo geri alÄ±m oranlarÄ± ve sÃ¼rdÃ¼rÃ¼lebilir stratejiler.
 </blockquote>
 
 <div style="margin-bottom: 1.5rem;">
 <p style="font-weight: 600; color: #195157; margin-bottom: 0.75rem; font-size: 0.95rem;"> Bu rehberde:</p>
 <ul style="list-style: none; padding: 0; margin: 0; display: grid; gap: 0.5rem;">
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> Neden Bu Kadar Ã–nemli?</li>
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> Klinik Ã‡alÄ±ÅŸma Verileri</li>
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> Neden Kilo Geri Geliyor?</li>
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> Kilo Geri AlÄ±mÄ±nÄ± Azaltma Stratejileri</li>
 <li style="display: flex; align-items: flex-start; gap: 8px; font-size: 0.95rem; color: #4b5563;"><span style="color: #10b981;"></span> Ne Zaman BÄ±rakÄ±labilir?</li>
 </ul>
 </div>
 
 <!-- Visual Summary Slider (swipe on mobile) -->
 <div style="margin: 2rem 0; padding: 1.5rem; background: #f8fafc; border-radius: 16px;">
 <p style="font-weight: 600; color: #195157; margin-bottom: 1rem; font-size: 0.95rem;"> GÃ¶rsel Ã–zet:</p>
 <div style="display: flex; overflow-x: auto; scroll-snap-type: x mandatory; gap: 12px; border-radius: 12px; -webkit-overflow-scrolling: touch; scrollbar-width: none; -ms-overflow-style: none;">
 <style>.visual-slider::-webkit-scrollbar { display: none; }</style>
 <a href="../../images/social/glp1-birakinca-ne-olur-slide1.jpg" target="_blank" style="scroll-snap-align: center; flex: 0 0 85%; border-radius: 12px; overflow: hidden; box-shadow: 0 4px 12px rgba(0,0,0,0.1);">
 <img src="../../images/social/glp1-birakinca-ne-olur-slide1.jpg" alt="Kapak" style="width: 100%; display: block;">
 </a>
 <a href="../../images/social/glp1-birakinca-ne-olur-slide2.jpg" target="_blank" style="scroll-snap-align: center; flex: 0 0 85%; border-radius: 12px; overflow: hidden; box-shadow: 0 4px 12px rgba(0,0,0,0.1);">
 <img src="../../images/social/glp1-birakinca-ne-olur-slide2.jpg" alt="Ä°Ã§erik" style="width: 100%; display: block;">
 </a>
 <a href="../../images/social/glp1-birakinca-ne-olur-slide3.jpg" target="_blank" style="scroll-snap-align: center; flex: 0 0 85%; border-radius: 12px; overflow: hidden; box-shadow: 0 4px 12px rgba(0,0,0,0.1);">
 <img src="../../images/social/glp1-birakinca-ne-olur-slide3.jpg" alt="Ã–zet" style="width: 100%; display: block;">
 </a>
 <a href="../../images/social/glp1-birakinca-ne-olur-slide4.jpg" target="_blank" style="scroll-snap-align: center; flex: 0 0 85%; border-radius: 12px; overflow: hidden; box-shadow: 0 4px 12px rgba(0,0,0,0.1);">
 <img src="../../images/social/glp1-birakinca-ne-olur-slide4.jpg" alt="CTA" style="width: 100%; display: block;">
 </a>
 </div>
 <p style="text-align: center; margin-top: 0.75rem; font-size: 0.85rem; color: #6b7280;"> KaydÄ±rarak diÄŸerlerini gÃ¶rÃ¼n</p>
 </div>
 
 <div style="display: flex; flex-wrap: wrap; gap: 8px; padding-top: 1rem; border-top: 1px solid #e5e7eb;">
 <span style="font-size: 0.8rem; color: #9ca3af;">#uzunyasa</span>
 <span style="font-size: 0.8rem; color: #9ca3af;">#saÄŸlÄ±k</span>
 <span style="font-size: 0.8rem; color: #9ca3af;">#glp1</span>
 <span style="font-size: 0.8rem; color: #9ca3af;">#birakinca</span>
 <span style="font-size: 0.8rem; color: #9ca3af;">#ne</span>
 </div>
 </div>
 <!-- END BLOG SUMMARY -->


<div class="cta-box">
 <h3>Size en uygun stratejiyi Ã¶ÄŸrenin</h3>
 <p>KiÅŸiselleÅŸtirilmiÅŸ deÄŸerlendirme iÃ§in testimizi tamamlayÄ±n</p>
 <a href="../test.html" class="cta-btn">Teste BaÅŸla â†’</a>
 </div>
 </div>
 </article>

 <footer><p style="font-size:0.85rem;font-style:italic;opacity:0.7;margin-bottom:0.5rem;">TÃ¼rkiye uzun yaÅŸasÄ±n diye.</p><p>Â© 2026 UzunYaÅŸa. <a href="https://tyzd.org" target="_blank" style="color:inherit;text-decoration:underline;">TÄ±pta Yapay Zeka DerneÄŸi</a> giriÅŸimidir.</p></footer>
<script src="../../scripts/animations.js"></script>
</body>
</html>
